Abcellute ceased operations on September 2016. Abcellute provides non-cryogenic cell preservation technology for the preservation and storage of fresh primary liver cells. Its primary strategy is to attain global adoption of its cell preservation platform technology, thereby providing the research community with enhanced cell systems to improve the management and development of key areas such as pre-clinical drug evaluation and regenerative medicine. Abcellute was formerly known as Cardiff Primacell. The company was founded in 2001 and is based in Birmingham, U.K.
Missing: Abcellute's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Abcellute's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Abcellute News
Nov 9, 2022
We use some essential cookies to make our services work. We'd also like to use analytics cookies so we can understand how you use our services and to make improvements. Accept analytics cookies
Abcellute Frequently Asked Questions (FAQ)
When was Abcellute founded?
Abcellute was founded in 2001.
Where is Abcellute's headquarters?
Abcellute's headquarters is located at Bdo Llp, Two, Snowhill, Birmingham.
What is Abcellute's latest funding round?
Abcellute's latest funding round is Dead.
Who are the investors of Abcellute?
Investors of Abcellute include Development Bank of Wales, Fusion IP, Cardiff University, HSBC and Wales Fund Managers.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.